Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Oropharyngeal cancer
Stage/Subtype:  stage III oropharyngeal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 72 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1216, NCI-2013-00500, NCT01810913
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients with Stage III-IV Oropharyngeal Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0825, NCI-2013-01879, NCT01893307
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Radiation Therapy with or without Cisplatin in Treating Patients with Oropharyngeal Cancer Previously Treated with Surgery
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 201207059, NCI-2012-01230, NCT01687413
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-141, NCI-2014-01268, 2013-003622-86, NCT02105636
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
Cetuximab and Recombinant Interleukin-12 in Treating Patients with Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: OSU 11010, NCI-2011-03631, 11010, CDR0000715306, 8860, 2011C0019, NCT01468896
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4981C00001, NCI-2014-01959, NCT02205333
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Vaccine Therapy and Cyclophosphamide in Treating Patients with Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J09100, NCI-2010-01868, CIR00005394, NA_00031401, NCT01088789
Intensity-Modulated Radiation Therapy in Treating Patients With Cancer of the Oropharynx
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: J0988, NCI-2009-01536, NCT01088802
Cetuximab Followed By Surgery and Chemoradiation Therapy in Treating Patients With Previously Untreated Stage III-IVA Head and Neck Squamous Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 08-013, NCI-2011-02479, NCT01218048
Cetuximab and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: UMCC 2009.009, NCI-2011-03619, HUM00027253, NCT01250522, NCT00904345
Docetaxel, Cisplatin, and Cetuximab in Treating Patients With Metastatic or Relapsed Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: ENT0033, NCI-2011-03271, 22329, SU-08222011-8290, NCT01437449
Radiation Therapy and Cisplatin in Treating Patients With Low-Risk HPV-Related Oropharyngeal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1120, NCI-2013-01074, 11-1557, NCT01530997
Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin after Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Refractory Human Papilloma Virus-Associated Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0116, NCI-2013-01524, 120116, 12C0116-H, 327146, P11943, NCT01585428
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RF-3501, NCI-2014-01403, LAP116153, NCT01711658
Start Over